UC, UC Health to launch Phase 3 clinical trial for COVID-19 vaccine
Vaccine uses a genetic code to produce proteins that may generate protective antibodies
Researchers at the University of Cincinnati and UC Health will host a Phase 3 clinical trial to evaluate the effectiveness of a vaccine for COVID-19, the respiratory illness caused by the novel coronavirus SARS-CoV-2.
UC is one of approximately 90 sites across the United States selected for the study, which will administer the vaccine candidate mRNA-1273 to volunteer participants and monitor its efficacy in eliciting an immune response that provides protection from COVID-19. The National Institute of Allergy and Infectious Diseases, (NIAID), part of the National Institutes of Health, is funding the study.
“UC was chosen because we have a proven track record of high-quality research and are the number one site in the NIAID-funded, AIDS Clinical Trials Group in the U.S. We are proud to bring leading-edge research to Cincinnati so that we can help our community battle the COVID-19 pandemic and be part of the solution,” said Carl Fichtenbaum, MD, professor in the Division of Infectious Diseases at the UC College of Medicine and a UC Health physician.
Fichtenbaum is co-investigator of the study and will serve as medical director.
Read the full story here.
Featured photo of COVID-19 vials by Colleen Kelley/UC Creative + Brand
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up on all UC's COVID-19 stories, read more #UCtheGood content, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
Related Stories
Local 12: Head injury survivor, doctor share importance of...
April 23, 2024
Local 12 spoke with patient Shane Shapiro and the University of Cincinnati's Laura Ngwenya about the importance of wearing a helmet following Shapiro's traumatic brain injury and recovery.
WVXU: Find your CPAP annoying? UC researchers are working on a...
April 22, 2024
Dr. Liran Oren is leading a research team at the University of Cincinnati developing a VortexPAP machine that takes advantage of vortex airflow technology. A preliminary clinical study with current CPAP users demonstrated that the VortexPAP can deliver the pressure levels that are used in the subjects’ CPAP therapy, but the mask is more comfortable to wear. It has a minimalistic design that is less intrusive and barely touches the patient’s face.
Cancer Center hosting event to kick off Ride Cincinnati 2024...
Event: May 3, 2024 12:00 PM
The University of Cincinnati Cancer Center is hosting a special kickoff event on Friday, May 3 from 12-1 p.m. in Kresge Auditorium to celebrate the opening of registration for Ride Cincinnati 2024, an annual fundraiser for local cancer research.